Immunic eyes transformative year ahead for MS therapy vidofludimus calcium – ICYMI [Video]

Immunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio joined Proactive to discuss the company’s progress in advancing its novel therapy vidofludimus calcium.

He discussed the significant milestones achieved in 2024, such as the positive interim analysis of the ENSURE trials in relapsing multiple sclerosis (MS) and the anticipation of the results from the CALLIPER progressive MS study in April 2025.

Proactive: Hello, you’re watching Proactive. I’m joined by Immunic chief operating officer Jason Tardio. Jason, very good to meet you, and Happy New Year. You joined Immunic about six months ago, in July last year. Tell us about your start, how the first months went, and what made you actually join Immunic?

Jason Tardio: Happy New Year to you as well, and thank you for having me. It’s been a wonderful six months. It’s been, as you can imagine, a busy six months. It’s a dynamic organization. There’s lots going on in Immunic—wonderful things, …